List view / Grid view
Experts from the US National Institutes of Health have written a commentary to promote a collaborative approach for the testing, scale-up and distribution of COVID-19 vaccine candidates.
Researchers have begun research to find how sustainable cold chain delivery systems for a COVID-19 vaccine can be established in resource-poor countries.
CEPI has announced that its funding for the Novavax COVID-19 vaccine candidate will go towards Phase I and Phase II trials as well as manufacturing costs.
The EMA has announced new regulatory changes that will help potential COVID-19 vaccines and therapeutics accelerate through development.
CEPI has announced it is urging organisations to apply for funding for the development and manufacturing of potential COVID-19 vaccines.
Pfizer and BioNTech have initiated Phase I/II trials in the US to determine the safety and optimal dose of four mRNA COVID-19 vaccine candidates.
The Coalition for Epidemic Preparedness Innovations (CEPI) and European Investment Bank (EIB) will work together to identify and fund vaccine projects for infectious diseases.
A new agreement between the University of Oxford and AstraZeneca will allow the former's COVID-19 vaccine candidate to be manufactured and distributed.
An outsourcing company has announced that Phase II, III and IV clinical trials of vaccines will continue at a growing number of sites, assessing the safety of each in light of COVID-19.
The World Health Organization (WHO) has launched its Access to COVID-19 Tools Accelerator, a collaboration to progress the development of coronavirus vaccines and therapeutics.
The EMA has announced its support for the International Coalition of Medicines Regulatory Authorities' call for global collaboration in the fight against COVID-19.
A polio vaccine designed to be incapable of evolving the ability to cause disease in humans has shown promise in a Phase I clinical trial.
The US National Institute of Allergy and Infectious Diseases (NIAID) has revealed its research priorities relating to COVID-19, including supporting the development and testing of potential therapeutics and vaccines.
A clinical trial to study a MERS vaccine has demonstrated success, say researchers, suggesting their technology could be repurposed to halt the spread of COVID-19.
The UK Bioindustry Association industry-led vaccine manufacturing group has welcomed a £14 million investment to support COVID-19 vaccine manufacturing.
